key: cord-1049966-0kjlq44q
authors: Riou, Catherine; Schäfer, Georgia; du Bruyn, Elsa; Goliath, Rene T.; Stek, Cari; Mou, Huihui; Hung, Deli; Wilkinson, Katalin A.; Wilkinson, Robert J.
title: Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells
date: 2021-06-18
journal: Eur Respir J
DOI: 10.1183/13993003.00285-2021
sha: 143a6138fb1a180a8d52dc9c43402e0b6818c462
doc_id: 1049966
cord_uid: 0kjlq44q

Rapid tests to evaluate SARS-CoV-2-specific T cell responses are urgently needed to decipher protective immunity and aid monitoring vaccine-induced immunity. Using a rapid whole blood assay requiring minimal amount of blood, we measured qualitatively and quantitatively SARS-CoV-2-specific CD4T cell responses in 31 healthcare workers, using flow cytometry. 100% of COVID-19 convalescent participants displayed a detectable SARS-CoV-2-specific CD4T cell response. SARS-CoV-2-responding cells were also detected in 40.9% of participants with no COVID-19-associated symptoms or who tested PCR negative. Phenotypic assessment indicated that, in COVID-19 convalescent participants, SARS-CoV-2 CD4 responses displayed an early differentiated memory phenotype with limited capacity to produce IFNɣ. Conversely, in participants with no reported symptoms, SARS-CoV-2 CD4 responses were enriched in late differentiated cells, co-expressing IFNɣ and TNFα and also Granzyme B. This proof-of-concept study presents a scalable alternative to PBMC-based assays to enumerate and phenotype SARS-CoV-2-responding T cells, thus representing a practical tool to monitor adaptive immunity due to natural infection or vaccine trials.

The outbreak of SARS-CoV-2 infection (causing the disease known as COVID-19) that first emerged in Wuhan, China in December 2019, was declared a global pandemic on 12 th March 2020, and is affecting all countries of the world, including those of Africa [1] . There is an urgent need to understand better the clinical manifestations and the pathogenesis of SARS-CoV-2 in order to develop relevant tools, including diagnostic tests, treatments and vaccines, to stop the spread of disease as well as strategies to best manage this disease in all population groups.

The clinical spectrum of COVID-19 is very wide, from asymptomatic through mild flu-like symptoms to severe pneumonia and death. Understanding what constitutes immune protection against SARS-CoV-2 is key to predicting long-term immunity and to inform vaccine design.

While much emphasis has been placed on the B cell and antibody response, it is not yet clear what type of immune response confers protection to SARS-CoV-2 [2] . Several studies suggest that the T cell response may play an important role in SARS-CoV-2 pathogenesis and reports indicating that patients lacking B cells can recover from SARS-CoV-2 infection further highlight the likely importance of T cell immunity [3, 4] . Additionally, accumulating evidence indicates that the presence of pre-existing, cross-reactive memory T cells specific for common cold coronaviruses may affect susceptibility to SARS-CoV-2 infection and partially explain the markedly divergent clinical manifestations of COVID-19 [5] [6] [7] [8] .

Efficient, sensitive and simple assessment of human T-cell immunity remains a challenge. Most commonly used T cell assays necessitate the isolation of peripheral blood mononuclear cells (PBMC), requiring significant amount of blood. Therefore, whole blood assays could be more advantageous than PBMC-based methods, by significantly reducing blood volume (~ 1 ml), making them more applicable to paediatric populations. Moreover, such assays are rapid, as they don't require cell separation, and preserve the physiologic cellular and soluble environments, mimicking better human blood condition. Here we report a rapid (~ 7 hrs) whole blood-based detection method of SARS-CoV-2-specific T cell responses with simple steps that could be adapted to settings of limited resources. This rapidly applicable assay could represent an easily standardizable tool to assess SARS-CoV-2-specific adaptive immunity to monitor T cell responses in vaccine trials, gain insight into what constitutes a protective response, or define the prevalence of SARS-CoV-2 T cell responders population wide.

The population studied consisted of healthcare workers (HCW, n=31, 29% male) recruited between July and September 2020, from Groote Schuur Hospital in Cape Town, the hardest hit region of the initial COVID-19 epidemic in South Africa [9] . Participants were classified according to i) reporting of COVID-19-associated symptoms, ii) whether a SARS-CoV-2 RNA PCR from a nasal or pharyngeal swab was performed and iii) SARS-CoV-2 PCR results. Based on these criteria, participants were subdivided into three groups: 1) persons with no COVID-19associated symptoms (n=15); 2) persons who reported symptoms but tested SARS-CoV-2 PCR negative (n = 7); and 3) persons who had COVID-19-associated symptoms and tested SARS-CoV-2 PCR positive (n = 9) ( 

The measurement of SARS-CoV-2 specific antibodies was performed using the Roche Elecsys ® [10] [11] [12] .

Patient plasma was evaluated for SARS-CoV-2 neutralisation activity using a SARS-CoV-2 pseudovirus infection assay. Single-cycle infectious SARS-CoV-2 pseudovirions based on the HIV backbone expressing the SARS-CoV-2 Spike (S) protein and a firefly luciferase reporter were produced in HEK-293TT cells [13, 14] by co-transfection of plasmids pNL4-3.Luc.R-.E-(NIH AIDS Reagent Program (#3418), Germantown, MD, USA) and pcDNA3.3-SARS-CoV-2spike Δ18 [15] . HEK-293TT cell culture supernatants containing the virions were harvested 3 days post transfection and incubated with heat-inactivated patient plasma at 5-fold serial dilutions for 60 min at 37˚C. Plasma/pseudovirus mixtures were then used for transfection of HEK-293T cells stably expressing the ACE2 receptor [16] . Cells were lysed 3 days post infection using the Promega cell culture lysis reagent (Promega Biosciences Inc., San Luis Obispo, CA, USA) and assessed for luciferase activity using a GloMax ® Explorer Multimode Microplate Reader (Promega Biosciences) together with the Luciferase assay system (Promega Biosciences).

Blood was collected in sodium heparin tubes and processed within 3 h of collection. The whole blood-based SARS-CoV-2-specific T cell detection assay was adapted from a previously reported whole blood intracellular cytokine detection assay designed to quantitate Mycobacterium tuberculosis specific T cells in small volumes of blood [17] . However, significant modifications have been made, including a reduced incubation time, the usage of a fixation buffer allowing the simultaneous lysis of red blood cells to streamline processing time, leading to faster acquisition of results [18] . Here, we adapted this assay to detect SARS-CoV-2 specific T cells using 

Even though RT-PCR is the most specific technique to detect acute SARS-CoV-2 infection, the positivity rate drops rapidly as soon as 10 days post-symptom onset, particularly in individuals with mild forms of COVID-19 [19, 20] . Hence, serology assays provide an important complement to RNA testing to identify individuals who have been sensitized by SARS-CoV-2.

Thus, to assess potential SARS-CoV-2 sensitization in participants who did not have a SARS-CoV-2 PCR test performed or tested PCR negative, the presence of SARS-CoV-2-specific antibodies (e.g. SARS-CoV-2 nucleocapsid-specific IgG) was measured and a SARS-CoV-2 pseudovirus neutralisation assay was also performed in all participants. While all participants with a positive SARS-CoV-2 PCR test exhibited in vitro anti-SARS-CoV-2 neutralizing activity and 8/9 (88.8%) had detectable SARS-CoV-2 nucleocapsid-specific IgG, none of the participants who tested negative or did not undergo PCR testing were positive for SARS-CoV-2 nucleocapsid-specific IgG ( But on the other hand, due to their high level of SARS-CoV-2 exposure, we cannot fully exclude SARS-CoV-2 infection, as while uncommon, COVID-19 confirmed patients with negative antibody results have been reported [21] .

Amongst the 31 participants tested, 58% (n=18) had a detectable SARS-CoV-2-specific CD4 T cell response (producing any of the measured cytokines, IFNɣ, TNFα or IL-2) using the described whole blood assay ( Figure 3A ). We then defined the magnitude and phenotype of SARS-CoV-2 -specific CD4 responses according to participants' clinical characteristics ( Figure 

While the proposed assay can be performed using a limited antibody panel to identify the frequency of SARS-CoV-2-responding T cells, by solely measuring cytokine production, the use of a more extensive antibody panel also permits definition of the phenotypic profile of these cells.

To this end, we included additional markers to assess the memory differentiation (CD27, CD45RA), cytotoxic potential (GrB) and activation profile (HLA-DR, CD38, Ki67, PD-1) of SARS-CoV-2-responding CD4 T cells.

shows that in all individuals with symptoms, SARS-CoV-2-specific CD4 T cells displayed almost exclusively (median: 97.7%) an early differentiated memory phenotype (ED:

CD45RA-CD27+). On the contrary, in 4/6 HCW with no symptoms, SARS-CoV-2-specific CD4

T cells exhibited a predominant late differentiated phenotype (LD: CD45RA-CD27-).

While the role of cytotoxic CD4 T cells is still unclear, the presence of these cells has been described in several viral infections [22] . We thus measured GrB expression in SARS-CoV-2- [26] [27] [28] [29] . Additionally, it is important to point out that all these studies were performed using PBMC and it is encouraging to find that a whole blood-based assay using limited amount of blood (< 1ml) yields comparable results.

Further analyses of the polyfunctional and phenotypic profile of SARS-CoV-2-specific CD4 T cells revealed that regardless of the clinical characteristics of the participants, the most prevalent cytokine detected in response to SARS-CoV-2 peptides was TNFα. These observations are in accordance with other studies pointing out an impairment of SARS-CoV-2 adaptive immune responses, characterized by low level of type I and type II interferon [30, 31] . However, it is also possible that the limited IFNγ production, we observed in this study, is related to the short stimulation time (e.g. 5 hrs) used in the assay. Nevertheless, this suggests that TNFα could be a more reliable target than IFN-γ, to detect SARS-CoV-2-specific CD4 T cell responses.

Additionally depending on their specificity, antigen-specific memory T cells can display highly variable differentiation profile [34] and the maintenance of elevated PD-1 expression on some virusspecific memory T cells (such as CMV or HCV) has been reported even after infection clearance [35] [36] [37] . Moreover, a recent publication showed that PD-1-expressing SARS-CoV-2-specific CD8 T cells are not exhausted, but functional in convalescent COVID-19 patients [38] . Further experiments will be needed to understand the impact of elevated PD-1 expression of SARS-CoV-

Lastly, SARS-CoV-2-responding CD4 T cells were qualitatively different between convalescent COVID-19 participants and participants who did not experience COVID-19associated symptoms. In the former group, SARS-CoV-2-specific CD4 T cells displayed almost exclusively an early differentiated memory phenotype; while in the latter group, SARS-CoV-2-

GrB.

Our study has several limitations. Our results rely on a small number of participants and need to be confirmed in larger cohorts. In the absence of a low SARS-CoV-2 exposure control group, we cannot speculate about the exact specificity of SARS-CoV-2 responding CD4 T cells detected in participants who are serology negative.

Moreover, technical optimization and validation are warranted to streamline the proposed assay and test its performance. A comparable approach using a whole blood IFN-release assay (IGRA), commonly used for the detection of Mycobacterium tuberculosis infection, has been recently applied to detect SARS-Cov-2 specific T cell response [39] . solution [40] , allowing to perform the cell stimulation and staining in batch at adequately equipped sites. Lastly, in this study, cell stimulation was performed using a pool of peptides covering the SARS-CoV-2 S, N and M proteins. In light of a recent publication showing that the discrimination between pre-existing cross-reactive response and COVID-19-induced response is dependent on specificity of the SARS-CoV-2 antigen used [41] , it appears that the peptide combination used in this study is not optimal to distinguished pre-existing cross-reactive SARS-CoV-2-reactive T cells from COVID-19-induced responses. Thus, the proposed assay may be further enhanced by using more targeted peptide pools with defined specificity for SARS-CoV-2 or seasonal coronaviruses.

Nevertheless, the primary objective of this study was to describe, as a proof-of-concept, a rapid and flexible whole blood assay, requiring very limited amount of blood, that could represent a powerful tool to investigate SARS-CoV-2 specific T cell responses both quantitatively and qualitatively even in COVID-19 paediatric cases.

The authors thank all the participants. 

The authors declare no conflict of interest. Correlations were tested by a two-tailed non-parametric Spearman rank test. 

Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa

Not just antibodies: B cells and T cells mediate immunity to COVID-19

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

COVID-19 makes B cells forget, but T cells remember

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Team obotGSHC-R. Clinical management of COVID-19: Experiences of the COVID-19 epidemic from Groote Schuur Hospital

Development and validation of the Elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2

Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Efficient intracellular assembly of papillomaviral vectors

Generation of HPV pseudovirions using transfection and their use in neutralization assays

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2

Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies

Disease extent and anti-tubercular treatment response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype regardless of HIV-1 status

Viral dynamics in mild and severe cases of COVID-19

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

COVID-19 confirmed patients with negative antibodies results

Cytotoxic CD4 T cells -Friend or foe during viral infection? Front Immunol

Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

T cell responses in patients with COVID-19

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition

High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity

High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome

The role of PD-1 in acute and chronic infection

PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, but Functional in Patients with COVID-19

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

An easy and reliable whole blood freezing method for flow cytometry immuno-phenotyping and functional analyses

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses